ライフサイエンスコーパス: recurrence-free survival

1 d cohorts (n = 592 with DRFS, n = 1,050 with recurrence-free survival).

2 Primary outcome was recurrence free survival.

3 n receptor (ER) status, lymph node invasion, recurrence free survival.

4 Margins >0.5 mm were not predictive of local recurrence free survival.

5 cal cohorts, wherein it associated with poor recurrence-free survival.

6 tionship between gamma-OHPdG and survival or recurrence-free survival.

7 esulting score was prognostic of overall and recurrence-free survival.

8 ionship between intratumor heterogeneity and recurrence-free survival.

9 C patients and yielded significantly shorter recurrence-free survival.

10 the tumor is critical to the patient's tumor recurrence-free survival.

11 lly significant improvement in breast cancer recurrence-free survival.

12 ncluded overall survival and disease-free or recurrence-free survival.

13 patients achieved the optimal outcome of 1-y recurrence-free survival.

14 essive tumor phenotypes and is predictive of recurrence-free survival.

15 ent completion, and patients who achieve 1-y recurrence-free survival.

16 c TGFBR2 expression correlated with improved recurrence-free survival.

17 Overall survival (OS) and recurrence-free survival.

18 suitable treatment regimens that can improve recurrence-free survival.

19 comes of the study were overall survival and recurrence-free survival.

20 ffected microwave ablation (MWA) success and recurrence-free survival.

21 ->A, located in exon 2), was associated with recurrence-free survival.

22 ation was not associated with improved local recurrence-free survival.

23 -3 and undetectable PTEN exhibited decreased recurrence-free survival.

24 body responses are associated with prolonged recurrence-free survival.

25 sectable ICCA demonstrated promising disease recurrence-free survival.

26 ent-refractory high Ki-67 scores and shorter recurrence-free survival.

27 us surgery versus surgery alone on abdominal recurrence-free survival.

28 on models were used to study the overall and recurrence-free survival.

29 8) were beneficial prognostic parameters for recurrence-free survival.

30 d with CRC T invasion and worse prognosis of recurrence-free survival.

31 avors neuronal differentiation and decreases recurrence-free survival.

32 with reduced prostate-specific antigen (PSA) recurrence-free survival.

33 association between SNP status and patients' recurrence-free survival.

34 ficantly associated with reduced overall and recurrence-free survival.

35 Recurrence-free survival 24 months after brachytherapy w

36 R0 resection (88% vs 88%, P = 0.999), median recurrence-free survival (33 vs 27 months, P = 0.502), a

37 c survival (73.2% vs. 75.3%, p = 0.844), and recurrence-free survival (61.2% vs. 66.3%, p = 0.742).

38 c survival compared with patients with IPNI (recurrence-free survival, 61% vs 76%; P = .009; disease-

39 overall survival (77.7% vs 76.0%, P = 0.64), recurrence-free survival (72.7% vs 71.2%, P = 0.70), or

40 iated tumors showed a trend toward decreased recurrence-free survival (8 vs 28 months, P = 0.075).

41 4 receiving LRT had similar 1, 3, and 5-year recurrence-free survival (89%, 77%, 68% vs 85%, 75%, 68%

42 to LRT; and had superior 1-, 3-, and 5-year recurrence-free survival (92%, 79%, and 73% vs 81%, 63%,

43 ssessed the association between genotype and recurrence-free survival, adjusted for baseline characte

44 The primary end point was recurrence-free survival after 2 or more years of CT sur

45 lantation at 12 US centers had a 65% rate of recurrence-free survival after 5 years, showing this the

46 reflect the prespecified interim analysis of recurrence-free survival after 90 events had been report

47 IgA was the strongest negative predictor of recurrence-free survival after achieving partial remissi

48 Though there were no differences in recurrence-free survival after curative therapy (median,

49 h which to predict 6-month and 1-year cancer recurrence-free survival after radical pancreatectomy, w

50 egulated genes significantly correlated with recurrence free survival among ER-positive and triple ne

51 The primary endpoint was recurrence-free survival, analysed in the per-protocol p

52 Conditional recurrence-free survival analyses suggest that the risk

53 rs correlated with a significant decrease in recurrence free survival and a significant increase in t

54 ma recurred in 11 patients (25%), with a 64% recurrence-free survival and 59% overall survival at 3 y

55 tions for pancreatic NETs are prognostic for recurrence-free survival and can be adopted in clinical

56 ts with CSCC and CPNI had poorer mean 5-year recurrence-free survival and disease-specific survival c

57 melanoma, showed significant improvements in recurrence-free survival and distant metastasis-free sur

58 Adjuvant therapy with imatinib prolongs recurrence-free survival and may improve overall surviva

59 the effects of cisplatin and carboplatin on recurrence-free survival and OS in mice bearing BRCA1/2-

60 NAMS is an excellent predictor of recurrence-free survival and overall survival in human l

61 ween this gene expression signature and both recurrence-free survival and overall survival in lung ca

62 BMP4 and SMAD7 were prognostic for improved recurrence-free survival and overall survival in patient

63 with adjuvant imatinib resulted in improved recurrence-free survival and overall survival, whereas d

64 Recurrence-free survival and post-LT recurrence were com

65 Recurrence-free survival and recurrence rates.

66 associated with poorer overall survival and recurrence-free survival and remained an independent pro

67 ariable sensitivity analysis, the utility of recurrence-free survival and the number of days in the h

68 ere tested for best-corrected visual acuity, recurrence-free survival, and adverse events scored by u

69 d to calculate the 10-year overall survival, recurrence-free survival, and disease-specific survival

70 mary endpoints were 5-year overall survival, recurrence-free survival, and freedom from recurrence ra

71 interest included survival, disease-free or recurrence-free survival, and quality of life.

72 ral, trials should use time to recurrence or recurrence-free survival as the primary end point and ti

73 The primary endpoint was abdominal recurrence-free survival, as assessed by the investigato

74 The primary outcome was recurrence-free survival assessed after database cut-off

75 The primary endpoint was recurrence-free survival, assessed by an independent rev

76 failed to confirm significantly better tumor recurrence- free survival at 1 year.

77 In the nivolumab plus ipilimumab group, recurrence-free survival at 1 year was 75% (95% CI 61.0-

78 ucing tumors also had significantly superior recurrence-free survival at 1, 3, and 5 years (88%, 74%,

79 Recurrence-free survival at 2 years was similar (47% and

80 Positive RVI score also portended lower recurrence-free survival at 3 years versus negative RVI

81 Recurrence-free survival at 3 years was 86% (95% CI 74-1

82 We used a non-parametric method to estimate recurrence-free survival at 3, 5, and 10 years after ini

83 lidated nomogram predicts the probability of recurrence-free survival at 5 years after PanNETs curati

84 res: The primary end point was breast cancer recurrence-free survival (BCRFS).

85 follow-up, nivolumab demonstrated sustained recurrence-free survival benefit versus ipilimumab in re

86 We noted no difference in median recurrence-free survival between the two groups (33.3 mo

87 osis (total and breast cancer mortality, and recurrence-free survival) both overall and in women who

88 Prediction of biochemical recurrence-free survival (BRFS) was assessed by Kaplan-M

89 ogic prognostic factors (10-year biochemical recurrence-free survival [bRFS], 29%; distant metastasis

90 and PTEN, significantly decreased patient's recurrence-free survival, but only NOTCH1 mutation remai

91 r overall importance for predicting two-year recurrence-free survival by incorporating variance from

92 The primary endpoint was recurrence-free survival by investigator assessment, and

93 wed independent substratification of reduced recurrence-free survival by Kaplan-Meier analysis.

94 pendently associated with the highest 2-year recurrence-free survival by multivariate analyses in two

95 sentation (primary vs recurrent disease) and recurrence-free survival by surgery type (open surgery v

96 Excellent long-term disease recurrence-free survival can be achieved in selected pat

97 treatment with ipilimumab results in longer recurrence-free survival compared with that for treatmen

98 verall (OS), recurrence-free, and liver-only recurrence-free survival, compared with non-PSH (P = 0.5

99 Median recurrence-free survival could not have been estimated i

100 Analyze conditional recurrence-free survival (cRFS) for rectal cancer patien

101 years, high-risk patients, with the shortest recurrence-free survival, demonstrated increased activat

102 Outcomes included recurrence-free survival, disease-specific survival, and

103 biomarker status is a prognostic factor for recurrence-free survival, distant metastasis disease-fre

104 The <8-mm group had reduced distant recurrence-free survival (DRFS) compared with the 8- to

105 Distant recurrence-free survival (DRFS) was assessed by TAILORx

106 A multigene predictor for distant recurrence-free survival (DRFS) was developed by the sup

107 Patients with FN AUS had recurrence-free survival equivalent to patients with pat

108 f 2.74 years (IQR 2.28-3.22), there were 528 recurrence-free survival events (234 in the ipilimumab g

109 At final analysis, 464 recurrence-free survival events had occurred (270 in the

110 iated with significantly reduced overall and recurrence-free survival following pancreatic cancer res

111 Median recurrence-free survival for carriers of the risk allele

112 Adjuvant ipilimumab significantly improved recurrence-free survival for patients with completely re

113 olecular signature predicted poor outcome of recurrence-free survival for patients with prostate canc

114 ternally validated RRS accurately stratifies recurrence-free survival for patients with resected PanN

115 CD24 and CD44 were associated with favorable recurrence-free survival for PCa patients.

116 anagement and were associated with excellent recurrence-free survival for superficial premalignant, m

117 Noninducible patients with LVEF>30% had a recurrence-free survival from cardiac death of 90% (95%

118 ients with high SULF1 expression have poorer recurrence-free survival (hazard ratio 4.1, 95% confiden

119 ls, tumor size 3 cm or more predicted poorer recurrence-free survival (hazard ratio: 1.60, 95% CI: 1.

120 sociated with increased local and in-transit recurrence-free survival [hazard ratio (HR) = 0.54; P =

121 The miR-21(High) group exhibited shorter recurrence-free survival [hazard ratio (HR), 1.71; P < 0

122 be a significantly poor prognostic factor of recurrence free survival (HR = 2.40, P = 0.005, 95%CI: 1

123 ard ratio [HR] = 2.13, P = .009) and reduced recurrence-free survival (HR = 1.70, P = .046) and MSS (

124 (HR: 1.64; 95% CI: 1.01, 2.66) and worsened recurrence-free survival (HR: 1.84; 95% CI: 1.26, 2.68).

125 0.002)] and in tumor stroma from TNBC cases [recurrence-free survival: HR, 2.59 (P = 0.013); BC-speci

126 mal growth factor receptor 2-negative cases [recurrence-free survival: HR, 3.67 (P = 0.006); BC-speci

127 s an independent prognostic marker for worse recurrence free survival in meningioma.

128 a potentially useful tool for prediction of recurrence-free survival in lung and breast cancer and v

129 ant and independent prognostic tool of human recurrence-free survival in lung and breast cancers.

130 ctor CD8(+) T cells (T(eff)) predicts longer recurrence-free survival in many types of human cancer,

131 teristic curves = 99% and 92%), and stratify recurrence-free survival in patients from two independen

132 elopments in radiation therapy have improved recurrence-free survival in patients with chordomas.

133 in/IGF-I gene expression signature predicted recurrence-free survival in patients with ER(+) breast c

134 ead acceptance that RAI improves overall and recurrence-free survival in patients with metastatic dis

135 ositively correlated with higher overall and recurrence-free survival in patients with prostate cance

136 et genes that independently predicted longer recurrence-free survival in patients.

137 atus and assessed their prognostic effect on recurrence-free survival in premenopausal women at risk

138 r analysis confirmed this result, with a 2-y recurrence-free survival in the (131)I-lipiodol and lipi

139 The primary endpoint was the recurrence-free survival in the intention-to-treat popul

140 it in terms of overall, cancer-specific, and recurrence-free survivals in patients with pT3N0M0 UTUC

141 y outcomes were overall survival (OS), local recurrence-free survival (L-RFS), and metastasis-free su

142 ssociated with an improved overall and liver recurrence-free survival (liver RFS) and disease-specifi

143 sociations with the primary endpoints: local recurrence-free survival (LRFS) and disease-specific sur

144 3-year disease-free survival (DFS) and local recurrence-free survival (LRFS).

145 all survival, disease-specific survival, and recurrence-free survival (median follow-up period, 70.8

146 Efficacy end points were local recurrence-free survival, metastasis-free survival, canc

147 urvival (MTV: P = 0.001; TGV: P = 0.004) and recurrence-free survival (MTV: P = 0.001, TGV; P = 0.002

148 th R0 versus R1 margins (2- and 5-year local recurrence free survivals of 53.5% and 20.4% vs 25.9% an

149 ay offer a new treatment strategy to improve recurrence-free survival of breast cancer patients.

150 y in most tumors, and it also predicted long recurrence-free survival of HER2-negative, stage III bre

151 six-SNP-based classifier precisely predicted recurrence-free survival of patients in three validation

152 aneous pulmonary metastases while prolonging recurrence-free survival only in immunocompetent mice.

153 atients (3% versus 9% versus 15%; P = 0.02), recurrence-free survival only trended toward significanc

154 Purpose To assess the diagnostic utility and recurrence-free survival over a minimum of 2 years follo

155 Endpoints were recurrence-free survival overall survival, and rate of C

156 am resulted in significantly higher rates of recurrence-free survival, overall survival, and distant

157 pattern of recurrence (P = 0.001) and 5-year recurrence free survival (P < 0.001).

158 colectomy patients had significantly reduced recurrence free survival (P = 0.032) but not stoma free

159 s a significant prognostic factor for better recurrence-free survival (P < 0.001), with a median time

160 free survival (DFS) (P < 0.001) and regional recurrence-free survival (P < 0.001).

161 This signature also significantly predicted recurrence-free survival (P = .029) and breast cancer -s

162 promoter mutations, correlated with reduced recurrence-free survival (P = 0.001).

163 ith shorter overall survival (p = 0.001) and recurrence-free survival (p = 0.005), while the other gr

164 iated with low survival (P < 0.0001) and low recurrence-free survival (P = 0.007).

165 hort significantly correlated to a prolonged recurrence-free survival (p = 0.029), similar to HNSCC c

166 tatistically significant difference in local recurrence-free survival (P = 0.13).

167 breast cancers was associated with decreased recurrence-free survival, particularly in patients treat

168 Overall and recurrence-free survival probabilities were estimated by

169 and cyclin D1, and reduced Numb, had reduced recurrence-free survival probability (HR = 4.35).

170 Slit2 correlated positively with overall and recurrence-free survival, providing clinical validation

171 ll tumors had the best outcome (5-year local recurrence-free survival rate of 91%).

172 mphatic density revealed significantly lower recurrence-free survival rates (P = 0.041) in C-MIN with

173 nts with unlimited epicardial RFA had better recurrence-free survival rates (P<0.001).

174 vant therapy with imatinib mesylate improves recurrence-free survival rates and may improve overall s

175 he NAFLD-HCC patients had a trend for higher recurrence-free survival rates compared to HBV and HCV-H

176 ated HCC patients had longer overall but not recurrence-free survival rates compared to patients with

177 The 5-y recurrence-free survival rates in the (131)I-lipiodol an

178 In this report, we compared the overall and recurrence-free survival rates of NAFLD HCC cases to pat

179 , 0.42 to 0.86; P = .005), and 3- and 5-year recurrence-free survival rates were 20.40% and 17.05% ve

180 fter therapy, respectively; post-transplant, recurrence-free survival rates were 78% and 65%, respect

181 Patient characteristics and recurrence-free survival rates were compared with those

182 all survival, disease-specific survival, and recurrence-free survival rates were not statistically di

183 3sigma expression levels predict overall and recurrence-free survival rates, tumour glucose uptake an

184 vival (Relative Risk: 2.129, p < 0.0001) and recurrence-free survival (Relative Risk: 1.299, p < 0.00

185 ntified with the longest and shortest 5-year recurrence-free survival, respectively, within the age a

186 The primary endpoint was local recurrence free survival (RFS) and the secondary endpoin

187 The median overall survival (OS) and recurrence free survival (RFS) for patients who received

188 c significance for overall survival (OS) and recurrence free survival (RFS) were determined by Cox pr

189 disease-specific survival (DSS P<0.001) and recurrence-free survival (RFS P<0.001).

190 1.92), DFS (HR: 1.45, 95% CI: 1.15-1.84) and recurrence-free survival (RFS) (HR: 1.32, 95% CI: 0.98-1

191 ties, the median, 1-year, 2-year, and 3-year recurrence-free survival (RFS) [overall survival (OS)] r

192 on of pathologic complete response (pCR) and recurrence-free survival (RFS) after neoadjuvant chemoth

193 d that 1 year of adjuvant imatinib prolonged recurrence-free survival (RFS) after resection of primar

194 Recurrence-free survival (RFS) and cancer-specific survi

195 Recurrence-free survival (RFS) and cancer-specific survi

196 Recurrence-free survival (RFS) and overall survival (OS)

197 HD7 expression was associated with increased recurrence-free survival (RFS) and overall survival (OS)

198 Recurrence-free survival (RFS) and overall survival (OS)

199 motherapy showed significant improvements in recurrence-free survival (RFS) and overall survival comp

200 At a median follow-up of 20.3 months, median recurrence-free survival (RFS) and overall survival were

201 The primary outcome was neck node recurrence-free survival (RFS) at 2 years.

202 Overall survival and recurrence-free survival (RFS) at 5 years were 81.9% (95

203 e survival (DFS), overall survival (OS), and recurrence-free survival (RFS) by treating neuropathy st

204 On the basis of 351 recurrence-free survival (RFS) events at a 1.25-year med

205 te the effect of KIT and PDGFRA mutations on recurrence-free survival (RFS) in patients with gastroin

206 se; how best to leverage this for predicting recurrence-free survival (RFS) is not established.

207 tients with low CHD5 expression had a median recurrence-free survival (RFS) of 5.3 vs 15.4 months for

208 red for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable

209 AJCC 7 Stage was not predictive of recurrence-free survival (RFS) or overall survival (OS).

210 patients with mutant RAS (P = 0.002); 3-year recurrence-free survival (RFS) rates were 33.5% with wil

211 The 1-, 3-, and 5-year recurrence-free survival (RFS) rates were 96%, 60%, and

212 Median recurrence-free survival (RFS) was 22 and 10 months for

213 Recurrence-free survival (RFS) was a secondary end point

214 ths, 1- and 5-year overall survival (OS) and recurrence-free survival (RFS) were 82%, 57%, and 77%, 5

215 Their overall survival (OS) and recurrence-free survival (RFS) were compared.

216 -treat and censored analyses of on-treatment recurrence-free survival (RFS) were performed, and explo

217 ogic characteristics, overall survival (OS), recurrence-free survival (RFS), and HCC recurrence (HCC-

218 ical and pathologic factors with SLN status, recurrence-free survival (RFS), and melanoma-specific su

219 conducted to pool the overall survival (OS), recurrence-free survival (RFS), and overall recurrence r

220 The primary objective was recurrence-free survival (RFS), and the secondary object

221 m outcomes, including overall survival (OS), recurrence-free survival (RFS), disease-specific mortali

222 Recurrence-free survival (RFS), disease-specific surviva

223 Recurrence-free survival (RFS), distant metastasis (DM),

224 factors were independent predictors of worse recurrence-free survival (RFS), namely, an NLR >/= 5 (P

225 Recurrence-free survival (RFS), the primary outcome meas

226 rformed the initial classifier in predicting recurrence-free survival (RFS).

227 model and estimate overall survival (OS) and recurrence-free survival (RFS).

228 Recurrence-free survival (RFS).

229 The primary end point was 12-month HG recurrence-free survival (RFS).

230 estimated, which can have an impact on their recurrence-free survival (RFS).

231 ors (AIs) have been associated with superior recurrence-free survival (RFS).

232 The primary end point was recurrence-free survival (RFS).

233 luded DF-free survival, failure pattern, and recurrence-free survival (RFS).

234 Primary outcome measurement was recurrence-free survival (RFS).

235 The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT)

236 , 1.8; 95% CI, 1.1 to 2.5) predicted a lower recurrence-free survival (RFS; all P < .01).

237 Recurrence-free survival (RFS; primary end point), dista

238 Recurrence-free survivals (RFS) were calculated using th

239 ent and tumor characteristics, and outcomes (recurrence-free survival [RFS] and overall survival [OS]

240 -specific survival (MSS), DFS, regional node recurrence-free survival (RNRFS) and DRFS compared with

241 fety and tolerability (primary outcomes) and recurrence-free survival (secondary outcome).

242 A Kaplan-Meier analysis of recurrence-free survival showed that the presence of tGI

243 or in combination with ipilimumab increased recurrence-free survival significantly compared with pla

244 tio of less than 1 showed dramatically lower recurrence-free survival than did patients with a ratio

245 with MSI-L and/or EMAST had shorter times of recurrence-free survival than patients with high levels

246 3) had a significantly decreased biochemical recurrence-free survival than those with a lower RSG 3 p

247 After 2 years of recurrence-free survival, the cumulative risk of recurre

248 The main outcome was recurrence-free survival; the secondary outcome was over

249 n a significant, nearly 30-month decrease in recurrence-free survival time (P-value: 0.034 and 0.007

250 aging and invasiveness, predicting a shorter recurrence-free survival time in noninvasive bladder can

251 Recurrence-free survival time was not significantly diff

252 DDIT4 expression is related to the outcome (recurrence-free survival, time to progression and overal

253 Recurrence-free survival times from alternative surveill

254 The optimal length of recurrence-free survival to distinguish between early (n

255 sed to evaluate the optimal cut-off value of recurrence-free survival to divide the patients into ear

256 vement on site of recurrence and overall and recurrence-free survival using individual patient data f

257 Local recurrence free survival was significantly different bet

258 For ACAIS, recurrence-free survival was 100% at 1 month and 96% (95

259 Recurrence-free survival was 11.5 months (95% CI 7.5-not

260 olumab plus ipilimumab group, whereas median recurrence-free survival was 12.4 months (95% CI 5.3-33.

261 The median recurrence-free survival was 14 months for all TERT-alt

262 In the intention-to-treat analysis, median recurrence-free survival was 24.4 months (95% CI 18.6-35

263 In the per-protocol analysis, median recurrence-free survival was 25.9 months (95% CI 19.8-46

264 Median recurrence-free survival was 26.1 months (95% CI 19.3-39

265 p, 16 (33%) entrants completed the study and recurrence-free survival was 36% (25-53).

266 Median abdominal recurrence-free survival was 4.5 years (95% CI 3.9 to no

267 n follow-up of 5.3 years, the 5-year rate of recurrence-free survival was 40.8% in the ipilimumab gro

268 Molecular recurrence-free survival was 43% (95% CI, 33% to 52%) at

269 io 0.75; 95% CI 0.64-0.90; p=0.0013); 3-year recurrence-free survival was 46.5% (95% CI 41.5-51.3) in

270 In the primary outcome analysis, mean recurrence-free survival was 467 days (95% CI, 445-489 d

271 9 months (36.2-52.3) with ipilimumab; 4-year recurrence-free survival was 51.7% (95% CI 46.8-56.3) in

272 (55.1-81.0); in the nivolumab group, 1-year recurrence-free survival was 52% (38.1-63.9) and at 2 ye

273 4%) of all 966 surgically treated cases, and recurrence-free survival was 62% (95% CI 59-65) at 3 yea

274 Recurrence-free survival was 64.5% in group A and 70.2%

275 Five-year local recurrence-free survival was 69%.

276 ched the 36-month trial completion point and recurrence-free survival was 72% (95% CI 64-80).

277 Median follow-up for recurrence-free survival was 8.5 months (IQR 2.9-19.5) i

278 [CI]: 80%, 93%) and 72% (95% CI: 62%, 83%), recurrence-free survival was 85% (95% CI: 79%, 91%) and

279 Three-year estimated local recurrence-free survival was 89.2% (95% CI, 0.748 to 0.9

280 The 3-year estimated distant recurrence-free survival was 90.3% (95% CI, 0.797 to 0.9

281 75 HCV-HCC transplant recipients, the 5-year recurrence-free survival was 93.4%, 84.8%, 73.9% for the

282 Three-year local recurrence-free survival was 96.9%, metastasis-free surv

283 The 3-year recurrence-free survival was 97.4% (95% CI, 96.4-98.5) i

284 Recurrence-free survival was described using Kaplan-Meie

285 Recurrence-free survival was higher in group 1, as compa

286 Association with overall survival and recurrence-free survival was investigated using the Kapl

287 ow-up of 28.4 months (IQR 17.7-36.8), median recurrence-free survival was not reached in the nivoluma

288 Five-year recurrence-free survival was significantly better in gro

289 Recurrence-free survival was the primary end point.

290 e 24-month Kaplan-Meier estimate for orbital recurrence-free survival was worse for the enucleation g

291 d all distant metastases were of MSFs, (iii) recurrence-free survival was worse in MSF than in the ST

292 The primary endpoint, recurrence-free survival, was significantly longer in th

293 Five-year overall survival and recurrence free survival were 73.6% and 29.3%, respectiv

294 tween margins and overall survival and local recurrence free survival were explored using Kaplan-Meie

295 Rates of 5-year recurrence-free survival were 30% in the laparoscopic gr

296 Five-year rates of overall and recurrence-free survival were predefined secondary end p

297 than 5 cm, in-hospital morbidity and 5-year recurrence-free survival were similar between the groups

298 Disease-specific and recurrence-free survivals were estimated with the Kaplan

299 easing T-category to significantly impact on recurrence free survival while increasing N-and T-catego

300 ompared with CRSa, CRS-HIPEC improved OS and recurrence-free survival, without additional morbidity o